Current and emerging monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies in treatment of lymphoma
The improvement in outcomes seen with the introduction of rituximab, a CD20 monoclonal antibody in combination with chemotherapy or as a single agent in the treatment of indolent non-Hodgkin lymphomas has paved the way for development of various forms of monoclonal antibodies that act in different w...
Збережено в:
| Автори: | , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Elsevier
2022-01-01
|
| Серія: | Leukemia Research Reports |
| Предмети: | |
| Онлайн доступ: | http://www.sciencedirect.com/science/article/pii/S2213048922000310 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|